Fisher Asset Management LLC Buys 99,427 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Fisher Asset Management LLC lifted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 25.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 494,924 shares of the company’s stock after buying an additional 99,427 shares during the quarter. Fisher Asset Management LLC owned about 0.77% of Viridian Therapeutics worth $11,260,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Quest Partners LLC raised its stake in Viridian Therapeutics by 344.0% during the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock worth $79,000 after acquiring an additional 4,692 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Viridian Therapeutics by 24.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after buying an additional 2,359 shares in the last quarter. AlphaCentric Advisors LLC boosted its holdings in Viridian Therapeutics by 108.3% in the 2nd quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock worth $163,000 after buying an additional 6,500 shares during the period. Arizona State Retirement System increased its stake in Viridian Therapeutics by 14.7% in the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock worth $171,000 after buying an additional 1,688 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Viridian Therapeutics during the third quarter valued at about $208,000.

Insider Transactions at Viridian Therapeutics

In other news, COO Thomas W. Beetham acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $23.41 per share, with a total value of $117,050.00. Following the completion of the purchase, the chief operating officer now directly owns 6,000 shares in the company, valued at $140,460. This trade represents a 500.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Stephen F. Mahoney purchased 21,400 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were purchased at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the purchase, the chief executive officer now owns 21,400 shares of the company’s stock, valued at approximately $499,262. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 1,626,400 shares of company stock worth $30,616,312. Insiders own 0.65% of the company’s stock.

Viridian Therapeutics Trading Down 0.2 %

Shares of VRDN opened at $21.87 on Thursday. The company’s fifty day simple moving average is $22.73 and its 200-day simple moving average is $17.30. The company has a market cap of $1.73 billion, a P/E ratio of -5.07 and a beta of 1.10. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a twelve month low of $11.40 and a twelve month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. As a group, analysts expect that Viridian Therapeutics, Inc. will post -4.04 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VRDN. HC Wainwright upped their price objective on Viridian Therapeutics from $27.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. TD Cowen initiated coverage on shares of Viridian Therapeutics in a report on Monday. They set a “buy” rating for the company. The Goldman Sachs Group lifted their price objective on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, September 12th. Oppenheimer reaffirmed an “outperform” rating and set a $28.00 target price (down from $31.00) on shares of Viridian Therapeutics in a research note on Monday, August 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research note on Thursday, September 19th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.33.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.